INTRODUCTION
============

As is the case worldwide, the disease burden of chronic disease is continually increasing in Korea ([@B1][@B2][@B3]). However, the quality of the treatment and management for chronic diseases remains low ([@B4][@B5]). In particular, the management quality in primary care medicine is at a relatively low level. For example, the rates of measurements of indicators of diabetes complications, such as glycosylated hemoglobin test, lipid profile test, and funduscopic examination, are lower in primary care clinics than in hospital-level facilities ([@B6]). Moreover, patient distrust of primary care and distortions of health-care delivery systems have caused many patients with chronic disease to prefer the services of hospital-level institutions ([@B7][@B8][@B9]).

As a key strategy for enhancing the management of chronic diseases in primary care clinics, the Korean Academy of Medical Sciences (KAMS) and the Korea Centers for Disease Control and Prevention have been jointly developing clinical practice guidelines (CPGs) for chronic diseases since 2011 ([@B10][@B11]). CPGs for hypertension and diabetes were developed in 2013. Several CPGs for major chronic diseases will continually be developed. In this process, the first step should be deciding priorities. Under the constraint of a limited funding, priority setting and resource allocation are required. Moreover, the fair selection of subjects, on the basis of evidence, is of fundamental importance to promote the development of CPGs and encourage the applications for guidelines in clinical fields ([@B12]).

Prioritization is a systematic approach to allocating resources for creating the \"best\" health-care system, subject to a variety of demands and limited resources ([@B13][@B14]). In addition, another strategy is to focus public attention and capabilities on key health issues ([@B15]). In decision making in complex health-care situations, a \"reasonable side\" and an \"intuitive side\" can be considered simultaneously when prioritizing alternatives for multiple criteria ([@B16][@B17]).

By establishing a special committee for priority setting and surveying objective and subjective assessments, this study identifies the chronic diseases that need to be prioritized in the development of CPGs in Korea.

MATERIALS AND METHODS
=====================

Overall process
---------------

The prioritization was performed as follows ([Fig. 1](#F1){ref-type="fig"}) : i) creating the CPG Priority-Setting Committee with representatives of 26 medical associations and CPG experts, ii) identifying the target chronic diseases, iii) collecting statistical data on those chronic diseases and examining the current developmental status of CPGs in Korea, iv) surveying the opinions of experts from the CPG Priority-Setting Committee by using the analytic hierarchy process (AHP) and a subjective assessment, and v) determining final priorities.

The CPG Priority-Setting Committee
----------------------------------

The CPG Priority-Setting Committee was composed of experts representing the users and developers of CPGs. There were 36 members including primary care physicians from the Korea Medical Practitioners Association representing the end user, members of the CPG committee of KAMS, and experts on the methods of guideline development.

Identifying target chronic diseases
-----------------------------------

The prioritized targets among the chronic diseases were extracted by using the Global Burden of Disease (GBD) and the 2012 Health Insurance Statistics Yearbook ([@B18]). The GBD classifies the diseases and injuries into 291 causes, whereas the International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10) classifies 22 classes, 267 categories, and 2093 subcategories. Among the 144 causes, those classified as noncommunicable diseases in the GBD were selected and matched with the ICD-10 categories. However, neoplasm, oral disorders, and hypertension and diabetes (the diseases for which CPGs are currently being developed by KAMS) were excluded. Finally, 41 chronic diseases were selected. Those diseases are the prioritized targets of this study.

Collection of statistical evidence and surveys of already developed CPGs
------------------------------------------------------------------------

Prioritization in the development of CPGs for chronic diseases could provide standards for the fair distribution of resources in order to decrease the social burden of those diseases. Therefore, to reflect the impact of a chronic disease on the judgment of priority, condition-level criteria focused on the burden of the disease were selected ([@B19]). Four criteria were considered: prevalence rate, mortality, medical expenses, and disability-adjusted life years (DALYs). Statistical data for the numbers of patients and medical expenses of disease-specific ICD-10 codes by categories were extracted from the Health Insurance Statistics Yearbook. The mortality rate was extracted from the database of the National Statistical Office of Korea. DALYs were extracted, according to cause, from the GBD. The prevalence rate was applied to the number of patients as a proxy indicator. All data were normalized by using the z-score to enhance the comparativeness between the criteria. To identify the current developmental status of CPGs in Korea, a mail survey to 133 affiliated medical associations was conducted through KAMS. Data on the burden of disease and a list of available CPGs were provided to the committee for consideration in the prioritization process.

Expert surveys
--------------

The expert survey was performed in 2 ways: objective measurement methods with the AHP (objective assessment) and asking about subjective priorities for CPG development (subjective assessment). AHP is a multicriteria analysis performed to determine priority by classes after classifying the criteria. This method consisted of 4 steps. The first step was to create a decision model ([@B20][@B21]). The AHP in this study comprised 3 levels ([Fig. 2](#F2){ref-type="fig"}). Level 1 involved the ultimate goal of the AHP; that is, the ranking of chronic diseases for which there is a need to develop CPGs. Level 2 involved the 4 criteria to be considered when CPGs are chosen for chronic diseases. We would have also liked to include variability as a criterion; however, we could not find data to clarify the current situation in Korea. Therefore, the developmental status of CPGs was surveyed instead of the variability. Level 3 involved identifying the 41 target chronic diseases. The AHP analysis model in this study is described below.

The second step was to determine the relative priorities of the criteria by making a series of pairwise comparisons among them with Saaty\'s discrete 7-value scale method ([@B20]). The third step was to calculate the geometric mean of each criterion in the matrix to obtain an approximate eigenvector that is the weighted value of the 4 criteria. Finally, the fourth step was to apply the weighted values to the standardized status (the z-score) of the 41 diseases. Consequently, the final prioritized diseases were determined.

On the other hand, the subjective assessment was performed by asking about subjective priorities for CPG development. Each disease was evaluated on a 7-point scale in terms of priority for CPG development, and the priority order was selected by summing the scores from the evaluators. The experts ranked the priorities by disease, excluding those diseases in their medical field. Therefore, the results were unaffected by the specific interests of expert societies.

Final decision making
---------------------

The top 20 diseases that received high priority ratings through the AHP and as suggested by subjective assessment each were selected.

RESULTS
=======

Target diseases and burden of disease
-------------------------------------

The 41 chronic diseases, their ICD-10 codes, and the burden of diseases are described in [Table 1](#T1){ref-type="table"}. Musculoskeletal diseases such as neck pain and osteoarthritis show a high prevalence and confers high medical expense but have low mortality rates. Although low in prevalence, cerebrovascular diseases present high DALY rates and high mortality.

Prioritizing by expert survey
-----------------------------

Of the members of the CPG Priority-Setting Committee, 36 were surveyed with the AHP. Of them, 22 answered (61.1% response rate). The AHP assessment showed that among the criteria for measuring the burden of disease, high importance was placed on mortality and medical expenses ([Fig. 3](#F3){ref-type="fig"}).

In both the AHP and subjective assessments, 7 diseases received an equal high priority: ischemic heart disease, cerebrovascular diseases, Alzheimer\'s disease and other dementias, osteoarthritis, neck pain, chronic kidney disease, and cirrhosis of the liver. The AHP showed that cerebrovascular diseases had the highest priority for CPG development; cardiovascular diseases such as ischemic heart disease and dyslipidemia were also ranked highly. The priority level of musculoskeletal disorders, such as neck pain, low back pain, and osteoarthritis, was also high. The subjective assessment showed that cardiovascular diseases such as ischemic heart disease, cerebrovascular diseases, and dyslipidemia had high rankings. The top 20 diseases that received a high priority are shown in [Table 2](#T2){ref-type="table"}.

DISCUSSION
==========

Recently, CPGs in various areas have been developed through the voluntary efforts of academic societies. However, despite the high burden of diseases and the clinical importance of CPGs, several major chronic diseases do not have CPGs ([@B22][@B23]). Moreover, some of the many CPGs that have been developed already require revision. By November 2013, there were 141 CPGs in Korea (see [Table S1](#S1){ref-type="supplementary-material"}). If the first edition of a CPG and its revised version are counted as 1, there are now 125 CPGs that have been developed by 76 academic societies or institutions in Korea. Of them, 83 CPGs are related to chronic diseases. Moreover, among those CPGs for chronic diseases, 40 guidelines had been developed in the last 5 yr (since 2010). Considering the rate of the production of new evidence in medicine and the worsening of the burden of chronic diseases, the need for developing more CPGs for chronic diseases is becoming increasingly pressing.

Among the criteria used to measure the burden of disease with the AHP, medical expenses and mortality were considered of high importance. Diseases with a high burden, such as cerebrovascular diseases, ischemic heart disease, musculoskeletal disease, and dyslipidemia, received high rankings that indicate the need for the development of CPGs.

Cerebrovascular diseases and ischemic heart disease are serious causes of death in Korea, and the medical expenses and numbers of patients with these diseases are very high. Furthermore, when the major risk factors-hypertension and diabetes-are considered, the disease burden becomes even greater ([@B24]). However, among the guidelines developed since 2010, only 13 have targeted cerebrovascular diseases and only 2 have a focus on ischemic heart disease. Furthermore, unfortunately, although many CPGs have been developed in recent years, they have focused on use in tertiary hospital institutions. CPGs reflecting the clinical features in primary care, the values and preferences of patients, and the environment of primary care institutions for the management of chronic diseases are insufficient. CPGs for disease prevention, lifestyle management, and follow-up care after the acute period of disease should be developed. For example, CPGs about primary and secondary prevention, screening, mild stable angina management, and indications for referring to tertiary institutions would be useful.

The situation for musculoskeletal disorders is even more serious. To date, despite the high burden of musculoskeletal disease, only 2 of such diseases-osteoporosis and rheumatoid arthritis-have CPGs in Korea. Given the high level of disease burden and the high variability in the behavior of health-care providers in musculoskeletal disorders ([@B25]), the development of more CPGs is urgently required. In addition, there is a pressing need for the development of guidelines on dementia, chronic renal failure, liver disease, asthma, and chronic obstructive pulmonary disease. Owing to the increase in the elderly population, the prevalence of dementia continues to increase ([@B26]). However, there is only one guideline related to dementia, which was developed in 2009, and it only covers disease diagnosis. Thus, the development of new guidelines for dementia is urgently needed, for application in various areas, including a set of detailed services about the prevention of disease, behavioral intervention, and pharmacological therapy, among others.

Moreover, the CPGs to be developed for those diseases are also expected to be consistent with national policies, in which the importance of cerebrovascular diseases, ischemic heart disease, and dementia has been increasing consistently. Those diseases are the main targets of \"Health Plan 2020,\" and risk factors such as smoking, drinking, exercise, and nutrition are the subjects of active management in the National Cerebrovascular Management Project, based on the National Health Promotion Act ([@B27]). In the case of dementia, the Dementia Management Act was enacted in 2012 and provides a legal foundation for prevention, early detection, and follow-up. Moreover, a dementia-screening program is being implemented throughout the country as a national policy. Furthermore, since the introduction of long-term care insurance, the frequencies of diagnosis, treatment, and care management by primary care physicians have increased ([@B28]). However, there is as yet no guideline for these physicians, which makes it difficult to provide appropriate services

In this study, we found a high need for CPGs for chronic diseases in Korea. Considering the rate of the production of new evidence in medicine and the worsening of the burden from chronic diseases, the need for developing more CPGs for more chronic diseases is becoming increasingly pressing.

In most countries with advanced CPG development, the establishment of public-private partnerships (PPPs) has been emphasized to develop the most reliable guidelines at a high level. Furthermore, this ensures the participation of various stakeholders in the development of CPGs and their quality control, leading to a social consensus for any conflict resolution caused by the CPGs ([@B29][@B30]). The United States has mandated the use of PPPs in developing CPGs ([@B31]). In Australia, the principles of development and a social consensus about the legal status of CPGs have been developed jointly by medical societies and the government ([@B32]). In Korea, however, most of the developmental activities depend on professionals. KAMS has led the development of CPGs, whereas the government\'s role has been confined to providing financial support. To develop high-quality CPGs, and to enhance implementation in practice, collaboration between professionals and the government is essential. PPP for financing, granting official status to accredited CPGs, and creating a favorable environment for implementation could lead to the development of CPGs with high quality.
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###### Table S1

One hundred forty-one CPGs lists developed since 1998 (as November 2013) in Korea

![Framework of CPGs priority setting.](jkms-30-1733-g001){#F1}
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![Distributions of weights according to AHP criteria. The top and bottom of the box indicates the 75th (Q3) and 25th percentile (Q1), respectively, and the horizontal line in the box means the 50th percentile (the median). The upper and lower ends of the whisker represent maximum and minimum, respectively.](jkms-30-1733-g003){#F3}

###### Target chronic diseases and disease burden by criteria

![](jkms-30-1733-i001)

  No.   Chronic diseases                                                         ICD-10                         Prevalence   Medical expense   DALYs           Mortality                           
  ----- ------------------------------------------------------------------------ ------------------------------ ------------ ----------------- --------------- ----------- ------ -------- ------- --------
  1     Dyslipidemia                                                             E78                            1,289,569    0.117             211,564,279     -0.213      0.41   -0.432   1.20    -0.285
  2     Alzheimer\'s disease and other dementias                                 F00, F01, F03, G30             354,272      -0.437            1,039,685,226   2.039       1.50   0.247    8.50    0.511
  3     Alcohol use disorders                                                    F10                            75,925       -0.601            216,835,500     -0.199      1.87   0.477    1.40    -0.264
  4     Schizophrenia                                                            F20                            102,186      -0.586            316,926,954     0.073       1.32   0.137    0.20    -0.394
  5     Unipolar depressive disorders                                            F31-F34                        728,867      -0.215            344,114,338     0.147       3.39   1.432    0.00    -0.416
  6     Anxiety disorders                                                        F40, F41, F43, F45, F48        877,848      -0.127            159,489,986     -0.355      2.36   0.786    0.00    -0.416
  7     Parkinson\'s disease                                                     G20                            79,930       -0.599            269,122,301     -0.057      0.22   -0.551   6.30    0.271
  8     Epilepsy                                                                 G40                            133,562      -0.567            104,390,909     -0.505      0.48   -0.389   0.90    -0.318
  9     Migraine                                                                 G43, G44                       1,085,399    -0.004            97,356,396      -0.524      2.37   0.792    0.00    -0.416
  10    Cataracts                                                                H25, H26                       1,164,780    0.043             457,299,954     0.455       0.11   -0.619   0.00    -0.416
  11    Glaucoma                                                                 H40                            635,019      -0.271            106,562,609     -0.499      0.04   -0.664   0.00    -0.416
  12    Refraction and accommodation disorders                                   H50, H52                       2,420,915    0.786             107,539,218     -0.496      0.08   -0.642   0.00    -0.416
  13    Other vision loss                                                        H53                            75,897       -0.601            6,891,870       -0.770      0.43   -0.419   0.00    -0.416
  14    Ischemic heart disease                                                   I20, I25                       164,697      -0.549            120,044,714     -0.462      3.90   1.745    26.80   2.506
  15    Cardiomyopathy and myocarditis                                           I42                            28,418       -0.630            38,388,516      -0.684      0.20   -0.569   2.90    -0.100
  16    Atrial fibrillation and flutter                                          I47-I49                        283,502      -0.479            157,156,111     -0.361      0.18   -0.578   10.10   0.685
  17    Hypertensive heart disease                                               I50                            115,070      -0.578            96,876,874      -0.525      0.55   -0.042   8.10    0.467
  18    Cerebrovascular disease                                                  I60, I61, I63, I65, I67, I69   778,628      -0.186            664,450,614     1.019       6.85   3.592    50.30   5.068
  19    Peripheral vascular disease                                              I70, I73                       99,478       -0.588            13,739,450      -0.751      0.04   -0.666   0.40    -0.373
  20    COPD                                                                     J44                            219,522      -0.516            133,757,481     -0.425      1.62   0.325    9.70    0.641
  21    Asthma                                                                   J45, I46                       1,877,132    0.465             242,414,169     -0.129      1.07   -0.024   3.00    -0.089
  22    GERD                                                                     K21                            3,519,136    1.436             364,589,088     0.203       0.37   -0.457   0.20    -0.394
  23    Peptic Ulcer Disease                                                     K25, K26, K27                  1,981,239    0.526             234,931,738     -0.150      0.18   -0.578   0.90    -0.318
  24    Gastritis and duodenitis                                                 K29                            5,537,390    2.631             337,765,932     0.130       0.06   -0.655   0.10    -0.405
  25    Cirrhosis of the liver                                                   K70, K71, K73, K74             381,576      -0.421            219,602,288     -0.191      2.54   0.897    13.20   1.023
  26    Gall bladder and bile duct disease                                       K80-K82                        205,448      -0.525            249,642,483     -0.110      0.19   -0.573   0.90    -0.318
  27    Urticaria                                                                L50                            2,438,071    0.796             117,628,575     -0.469      0.17   -0.583           -0.416
  28    Rheumatoid arthritis                                                     M05, M06                       282,061      -0.479            156,199,090     -0.364      0.60   -0.316   0.40    -0.373
  29    Gout                                                                     M10                            292,185      -0.473            48,854,668      -0.656      0.01   -0.684   0.10    -0.405
  30    Osteoarthritis                                                           M15-M17, M19, M24, M25         5,132,022    2.391             1,264,330,619   2.650       1.49   0.238    0.00    -0.416
  31    Low back pain                                                            M40,M41, M45-M49               2,696,010    0.949             781,263,369     1.336       5.90   2.997    0.30    -0.384
  32    Neck pain                                                                M50-M54                        7,669,057    3.892             1,411,443,671   3.050       3.18   1.298    0.00    -0.416
  33    Tubulointerstitial nephritis, pyelonephritis, urinary tract infections   N02, N13                       75,221       -0.602            28,200,950      -0.712      0.11   -0.620   0.20    -0.394
  34    Chronic Kidney Disease                                                   N18                            150,862      -0.557            1,341,916,546   2.861       1.02   -0.051   6.60    0.303
  35    Urolithiasis                                                             N21                            33,251       -0.627            7,691,439       -0.767      0.05   -0.659   0.00    -0.416
  36    Other urinary diseases                                                   N28, N31, N32                  388,426      -0.417            60,269,087      -0.625      0.06   -0.656   0.00    -0.416
  37    Benign prostatic hyperplasia                                             N40                            974,458      -0.070            287,746,721     -0.006      0.36   -0.465   0.00    -0.416
  38    Male infertility                                                         N46                            42,858       -0.621            2,751,215       -0.781      0.01   -0.687   0.00    -0.416
  39    Endometriosis                                                            N80                            84,455       -0.596            41,645,769      -0.675      0.04   -0.667   0.00    -0.416
  40    Premenstrual syndrome                                                    N94                            159,854      -0.552            5,086,714       -0.775      0.08   -0.644   0.00    -0.416
  41    Female infertility                                                       N97                            147,078      -0.559            20,289,735      -0.733      0.00   -0.688   0.00    -0.416

ICD, international statistical classification of diseases and related health problems; N, numbers; Z, z-score; 1 USD, 1,000 Korean won; %, prcent of total DALYs in Korea; R, number of deaths per 100,000.

###### Priorities in chronic diseases for the development of CPGs by AHP and subjective assessment
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  Rank   AHP                                        Subjective assessment
  ------ ------------------------------------------ ------------------------------------------
  1      Cerebrovascular disease                    Ischemic heart disease
  2      Neck pain                                  Cerebrovascular disease
  3      Low back pain                              Alzheimer\'s disease and other dementias
  4      Osteoarthritis                             Dyslipidemia
  5      Ischemic heart disease                     Asthma
  6      Chronic Kidney Disease                     Osteoarthritis
  7      Alzheimer\'s disease and other dementias   COPD
  8      Gastritis and duodenitis                   Neck pain
  9      Cirrhosis of the liver                     Chronic Kidney Disease
  10     Unipolar depressive disorders              Cirrhosis of the liver
  11     GERD                                       Benign prostatic hyperplasia
  12     Asthma                                     Cataracts
  13     COPD                                       Parkinson\'s disease
  14     Anxiety disorders                          Unipolar depressive disorders
  15     Migraine                                   Low back pain
  16     Atrial fibrillation and flutter            Peptic Ulcer Disease
  17     Peptic Ulcer Disease                       Alcohol use disorders
  18     Cataracts                                  Schizophrenia
  19     Alcohol use disorders                      GERD
  20     Urticaria                                  Gastritis and duodenitis

AHP, analytic hierarchy process; GERD, gastroesophageal reflux disease; COPD, chronic obstructive pulmonary disease.
